TW449478B - Pharmaceutical compositions for healing and repair of connective tissue attachment - Google Patents
Pharmaceutical compositions for healing and repair of connective tissue attachment Download PDFInfo
- Publication number
- TW449478B TW449478B TW085106195A TW85106195A TW449478B TW 449478 B TW449478 B TW 449478B TW 085106195 A TW085106195 A TW 085106195A TW 85106195 A TW85106195 A TW 85106195A TW 449478 B TW449478 B TW 449478B
- Authority
- TW
- Taiwan
- Prior art keywords
- bone
- bmp
- patent application
- carrier
- tendon
- Prior art date
Links
- 210000002808 connective tissue Anatomy 0.000 title claims abstract description 25
- 230000035876 healing Effects 0.000 title claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims 5
- 230000008439 repair process Effects 0.000 title description 10
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 88
- 210000002435 tendon Anatomy 0.000 claims abstract description 50
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 210000001519 tissue Anatomy 0.000 claims abstract description 21
- 230000008929 regeneration Effects 0.000 claims abstract description 15
- 238000011069 regeneration method Methods 0.000 claims abstract description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 239000000515 collagen sponge Substances 0.000 claims description 17
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 15
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 15
- 102000008186 Collagen Human genes 0.000 claims description 15
- 108010035532 Collagen Proteins 0.000 claims description 15
- 229920001436 collagen Polymers 0.000 claims description 14
- 229920000642 polymer Polymers 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 10
- 238000001356 surgical procedure Methods 0.000 claims description 10
- 239000001913 cellulose Substances 0.000 claims description 9
- 229920002678 cellulose Polymers 0.000 claims description 9
- 230000002079 cooperative effect Effects 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 101150061927 BMP2 gene Proteins 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims description 3
- 102000045896 human BMP2 Human genes 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000001582 osteoblastic effect Effects 0.000 claims description 2
- 230000004221 bone function Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 27
- 210000003041 ligament Anatomy 0.000 abstract description 12
- 230000001965 increasing effect Effects 0.000 abstract description 6
- 238000002278 reconstructive surgery Methods 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 abstract 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 abstract 1
- 206010063560 Excessive granulation tissue Diseases 0.000 abstract 1
- 230000003190 augmentative effect Effects 0.000 abstract 1
- 229940112869 bone morphogenetic protein Drugs 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 210000001126 granulation tissue Anatomy 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 41
- 230000002188 osteogenic effect Effects 0.000 description 13
- 210000003414 extremity Anatomy 0.000 description 12
- 210000003127 knee Anatomy 0.000 description 11
- 210000002303 tibia Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 210000003811 finger Anatomy 0.000 description 5
- 210000004417 patella Anatomy 0.000 description 5
- 210000005239 tubule Anatomy 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 2
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108091027305 Heteroduplex Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 2
- 230000033558 biomineral tissue development Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000512 collagen gel Substances 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003195 fascia Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- -1 polyoxyethylene, carboxyvinyl Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 210000002832 shoulder Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 1
- 101150072730 Bmp6 gene Proteins 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 description 1
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 1
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 description 1
- 101710204281 Growth/differentiation factor 6 Proteins 0.000 description 1
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010065433 Ligament rupture Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 210000004439 collateral ligament Anatomy 0.000 description 1
- 229920000891 common polymer Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229910052704 radon Inorganic materials 0.000 description 1
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000012079 reconstructive surgical procedure Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/10—Materials or treatment for tissue regeneration for reconstruction of tendons or ligaments
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Prostheses (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Dental Preparations (AREA)
- Peptides Or Proteins (AREA)
Description
A7 449478 __B7_ 五、發明説明(】) 本發明的領域 本發明乃有關於組織修復的領域,特別是,結締組織 如肌腱,軟骨或韌帶對骨頭之間功能性附著的再生。此功 能性的附著可能因外傷或壓力,或因退化性或先天性疾病 而被損壞。因此,本發明在重建手術或其他對於結締組織 和骨頭之間功能性附著的再生的步驟上是有用的。 本發明的背景 需要的發生和原因的背景 雖然有一些重建手術步驟是依靠結締組織,特別是肌 腱或韌帶對骨頭的固定癒合或附著,但卻很少人瞭解有關 肌腱對骨頭接觸面的癒合方法。由於對骨頭做移植固定的 部位是移植後初期最脆弱的部分,因此改善初期移植固定 之强度的方法具有重要的臨床應用。而這對施行膝部,肩 部,腎部,手部,腳踩和肘部之手術時特別重要。 肌腱或韌帶附著至骨頭上的發展情形了解得很少。而 此附著部位是由膠原纖維,已知是Sharpey氏纖維#居 間連接的,此纖維是由肌腱連接到骨頭不間斷的。Sharp-ey氏纖維被認爲是由發育中的骨骼藉韌帶的進行性礦質化 或在生長期間促進骨頭發育的骨膜膠原纖維所形成的。硏 究顯示骨頭到肌腱的癒合藉由骨頭向內生長至纖維血管接 觸面組織,而此組織最初是在肌腱和骨頭間形成。而接觸 面組織和後來的向內生長至外部肌腱的骨頭有進行性礦質 化產生。不管骨頭生長至膠原組織中的證據,此種骨頭向 本紙張尺度適用中國國家標準(CNS > A4規格(U0X297公釐) ^------ΐτ------Μ - k- (诗先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 ^49478 A7 B7____ 五、發明説明(2) (請先閱讀背面之注意事項再填寫本頁} 內生長的機轉,以及附著的效力和强度仍不確定,一先前 有關肌腱到骨頭癒合的硏究顯示肌腱和骨頭之間纖維組織 接觸面的形成。Rodeo et al.,J.Bone and Joint Surgery, 7 5-A: 1 7 9 5-1 8 0 3 (1 9 9 3) 〇 因此,不管在這領域許多實質上的努力,獲得一個修 復結締組織,如肌腱或韌帶和骨頭間功能性附著的有效方 法是必需的。 本發明的摘要 線 經濟部中央標準局員工消費合作社印製 本發明對結締組織和骨頭間功能性附著的再生,提供 了方法和組成物。尤其,本發明也包含了治療病患其肌腱 或韌帶對骨頭具有脫離或退化性附著之方法。一些實施例 包括了對膝部,肩部,手部,腳踝和肘部的重建手術。本 發明可證明有效的特別部位包括前十字韌帶(A C L )或 旋轉環帶的重建。本發明的方法和組成物之所以有利乃在 於它們使用成骨蛋白質,此蛋白質可藉由DNA重組技術 而得,因此可以無限地供應。本發明的方法和組成物對於 附著組織的再生更有利,可促進此再生或使之有更大的最 終强度,並且在結締組織和骨頭間所形成之附著可在手術 後或修復開始作用時很快的達到一功能性的强度。本發明 的方法和組成物更有利於誘導結締組織和骨頭間功能性附 著的再生,並減少或避免在組織類型間接觸面纖維或粒狀 組織形成。 本發明的方法特別適用於在骨頭小管中的圓形肌腱或 本紙張尺度適用中國國家標準(CNS ) A4規格(2丨0X297公釐) ' 一 49478 -^78 : :_^__ 五、發明説明(3 ) (請先閱讀背面之注意事項再填寫本頁} 在骨頭表面的扁平形肌腱的固定。一些臨床的實施例是有 關聯的。一個普通的臨床實施例是前十字韌帶(AC L ) 的重建。重建可藉由利用由脛骨和膝蓋骨兩者所阻斷的膝 蓋骨韌帶中央第三節和一被附著的骨頭來執行,或利用半 腱性和薄的肌腱來執行。利用膝羞骨肌腱的好處包括立即 的骨頭固定,使得手術後很炔的恢復並增加强度。然而, 利用膝蓋骨韌帶的中央第三節會有不良的後遺症,包括膝 蓋骨骨折,膝蓋骨韌帶斷裂,以及膝蓋骨與股骨的接合處 之變性。利用半腱性和薄的肌腱的好處包括較早得到癒合 的結果,膝部的伸肌構造不會斷裂,在手術一年後有較好 的四頭肌强度,並且可使腿筋的强度損失達到最低。而最 主要的陷阱是有關於在骨頭小管內之肌腱之固定之强度以 及在固定部位移植失敗的危險。此雨個韌帶重建的方法間 主要的不同是移植物的固定。 經濟部中央標準局員工消費合作社印製 使用BMP以增加肌腱對骨頭的癒合,可使利用半腱 性和細的肌腱進行A C L重建的方法更理想,如此可預防 膝蓋骨的損害和天生在膝蓋骨軔帶所得的伴隨之伸肌構造 的斷裂。臨床前的評估顯示r hB Μ P—2可改善骨頭對 肌腱移植物的早期癒合,誠如被組織學和生物力學的評估 所証實的。增加肌腱對骨頭固定的强度將可更早及更有效 的修復,而導致更早恢復正常的活動,工作或運動。 其他本發明可直接適用的一般臨床實施例包括下列: 旋轉環帶肌腱對肱骨較大結節的修復,關節窩邊綠對肩胛 骨頭部的再附著,利用一置於通過骨頭小管的肌腱移植物 本紙張尺度適用中國國家標準(CNS ) Α4规格(210 X 297公釐) 經濟部中央標準局負工消費合作社印製 4 9 478 at ___B7_ 五、發明説明(4 ) 所進行之側邊腳踝韌帶之重建,利用被固定在骨頭表面或 通過骨頭小管的肌腱移植物所進行之肘部或膝部醫學上側 邊韌帶之重建,利用被置於骨頭小管內之肌腱移植物來進 行拇指尺骨側邊軔帶之重建,以及進入骨頭小管或在指( 趾)骨表面之指(趾)的屈肌成伸肌之修復。本發明廣泛 地適用於結締組織對骨頭進行再附著的任何情況,不管是 在骨頭的表面或是在骨頭的小管內。 本發明的詳細描述 根據本發明,提供了方法和組成物以治療需進行重建 手術來修復結締組織和骨頭間功能性附著的病人。對於全 部附著結構可能被影饗的修復或改良,本方法和組成物是 有利的:對肌腱或韌帶,側邊骨頭,以及功能性附著。本 發明方法包括了適用於需要重建手術的部位,或損害的部 位,結締組織對骨頭的撕裂或分離,而組成物的量包含了 一個或多個純化的成骨蛋白質,其對結締組織對骨頭的功 能性附著的再生是有效的。本方法更包含了給予一含有純 化或重組的成骨蛋白質的組成物到有必要進行在一適合的 載體存在下附著的結締組織對骨頭進行再生的部位,因而 結締組織,骨頭和功能性附著結構被再生,且減少發生在 附著部位的纖維化或粒狀組織。本組成物與一有效之載體 合併給予較佳。本發明的方法之主要好處之一是它可使結 締組織,骨頭和功能性附著結構在加速的方法下進行可被 控制的再生,因而此附著比起用相同的步驟但不加成骨蛋 本紙張尺度適用中國國家標準(CNS ) Α4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
,1T 4』9 47 8 A7 _____ B7_ 五、發明説明(5 ) 白質的情況,在較早的時間可獲得更大的功能性强度。 成骨蛋白質 成骨蛋白質將之分類爲蛋白質的亞網較佳,已知一般 爲骨頭成形蛋白質(BMP s ),其已表現出具有成骨活 性,以及其他成長和不同類型的活性。這些BMP S包括 有 BMP-2,BMP-4 , BMP— 5,BMP-6, BMP-7 , BMP— 8,BMP-9,BMP-1 0 , BMP— 1 1 ,BMP— 1 2 以及 BMP— 1 3,也包括 蛋白質的TG F - 超科的其他種類,如成長和不同的因 子,或是GDF s ,和MP5 2。這些BMP蛋白質中的 一種之結構已在美國專利4 ,8 7 7 ,8 6 4 ; 5,108,922:5,013,649: 5»116*738;5>1〇6»748; 5 . 187,076:5 - 141,905;和在卩(:丁 申請書W091/18098;W093/00432: W09 4/2 6 8 9 3 以及W09 4/2 6 8 9 2 :及審 經濟部中央標準局員工消費合作社印製 査中的專利申請書,在1 9 9 4年1 2月2 2日編檔之連 續期數0 8/3 6 2 6 7 0被發表出來。GDFs的一種 中之結構在W094/15965, W094/15949 ;W 095/01801 ; W095/01802 ;W 094/21681 ; W09 4/1 5 9 6 6中被發表出來。MP5 2的結構在 W 09 3/1 6 0 9 9中被發表出來。上述申請書的發表 本紙張尺度適用中國國家標準(CNS ) A4规格(210x297公釐) 經濟部中央標準局員工消費合作杜印製 五、發明説明(6) 內容併入本文爲參考資料。BMP以BMP — 2較佳,其 順序已在美國專利5,0 1 3,6 4 9中被發表,其發表 內容併入本文爲參考資料。其他在此技藝中的已知之 BMP s也可被利用。目前,最佳的BMP是BMP— 2 〇 BMP可重組產生,或由蛋白質組成物中純化而來。 BMP可以與其他的BMP s形成同質二量體或是異質二 量體(例如,由BMP — 2和BMP_ 6各一單體所組成 的異質二量體)或是和TGF -点超科的其他種類,如活 心生物,抑制物及TGF_/? 1形成同質二量體或異質二 量體(例如,由BMP和TGF — 超科的一相關種類各 一單體所組成的異質二量體)。這類的異質二量體蛋白質 的實施例已以舉例方式在已出版的P C T專利申請書 W〇9 3/0 9 2 2 9中被描述,其詳細內容併入本文爲 參考資料。 成骨蛋白質在此的有效量是指此量可刺激滲透的原始 細胞所增加的成骨活性,並且也與所須治療的損害的大小 和種類,以及所使用的載體有關。一般而言,所使用的蛋 白質量是在大約0. 05到大約1. 5毫克的範圍內。 在一較佳的具體表現中,成骨蛋白質是和一有效量的 可以誘導似肌腱或似韌帶組織產生的蛋白質一起給與。這 類蛋白質包括BMP— 1 2,BMP— 1 3以及BMP — 1 2超科的其他種類,以及BMP5 2。這些蛋白質以及 它們對似肌腱和似韌帶組織的再生之使用在美國申請書連 本紙張尺度適用中國國家標準(CNS ) A4规格(2IOX297公釐) (讀先閱讀背面之注意事項再填寫本育) -ο. 啟 經濟部中央標準局貝工消費合作社印製 449478 五、發明説明(7) 續期數 08/362,670,於 1994 年 12月 22 日編檔著已發表出來,其發表內容併入本文爲參考資_。 在另一個較佳的具體表現中,將由一單If單位是成骨蛋白 質如BMP - 2,而另一單體次單位是誘導肌腱蛋白質, 如BMP—12所形成之異質二量體,依照下述之方法給 與,以期誘導出結締組織和骨頭間功能性附著的瑕成。 載體 在本發明中實際操作上可做爲有效載體的物質包括具 有黏性和極性之藥學上可接受之物質,例如,當將之加至 骨頭成形蛋白質時,會形成一具有專用的控制特性(也就 是維持在損害的部位不會太鬆軟濕滑),可適用於結締組 織到骨頭附著的再生的部位。將載體加至骨頭成形蛋白質 中可使蛋白質在疾病或損害的部位錐持一段足夠的時間, 使得蛋白質能夠增加滲透的哺乳動物原始細胞的再生成骨 活性的其他天生速率,並且可形成一個空間,使得新的組 織可以生長並允許細胞的向內生長。而載體也可使得骨頭 成形蛋白質超過一時間間隔由受傷或損害部位釋放出來, 使得原始細胞的再生成骨活性的速率增加得最理想。 最佳的一類載體包含有膠原質物質。較佳的膠原質物 質包括Collastat^^HelistatR膠原質海綿狀物質( Integra Lifesciences Corp. Plainsboro,N‘J.)。其他 在本發明中適於使用的膠原質物質在美國專利 5,206, 028:美國專利5,024, 841,美 本紙張尺度適用中國國家標準(CNS ) A4規格(2] 0 X 297公釐) (請先聞讀背面之注意事項再填寫本頁) -訂· 線 49 47 8 a? __B7 五、發明説明() 8 國專利5,2 5 6,4 1 8中有描述。膠原質載體以海綿 狀物的型式較佳。此膠原質海綿狀物可以事先將此海綿狀 物浸在所需體積和濃度的蛋白質中一段合適的時間而使之 與蛋白質滲合在一起。膠原質海綿狀物和蛋白質浸潤滲合 在一起較佳的範圍是由大約1 0%到大約1 5 0%ν/ν 〔mi?蛋白質/ cc乾燥之海綿狀物〕,而更佳的是大約 1 0到大約6 0%ν/ν。也可二者擇其一,在製造過程 中將蛋白質吸附到膠原質海綿狀物中。在這個情況中,將 骨頭形成蛋白質在製造過程中加至膠原質海綿狀物中較佳 ,並用冷凍乾燥形成一單一的產物。所加的蛋白質較佳的 比例是由大約1 0到大約1 5 0 % v / v ,更隹的範圍是 由大約6 0到大約8 0%ν/ν。在本發明中可使用的其 他型式的膠原質是膠原質凝膠,以及交叉連結的聚合膠原 質。 經濟部中央標準局員工消費合作社印製 (請先閲讀背面之注意事項再填寫本頁) 另一種較宜用於骨頭成形蛋白質的載體是多孔性微粒 聚合物,在美國專利5,1 7 1,5 7 9中有詳細的描述 ,而其全部內容併入本文爲參考資料,而較佳的多孔性微 粒聚合物是多乳酸和多羥基乙酸的共同聚合物。而蛋白質 和聚合物由一使接收製劑,如自體血液來接收較佳。在本 發明中所使用的二者擇一的另一載體是成骨蛋白質,多孔 性微粒聚合物和另一種使接收製劑,如纖維素物質的組合 。其他較佳的使接收製劑包括有玻尿酸,藻膠酸化鈉,聚 乙二醇,氧化聚氧乙烯,羧基乙烯基聚合物和聚乙烯醇。 作爲使接收製劑有最佳具體表現的是羧基甲基纖維素,這 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210X297公釐) -11 - 經濟部中央標準局員工消費合作社印製 44947a 五、發明説明() 9 些組成物在已出版 中有描述,而其全 白質使接數劑以大 度存在較佳。而此 也可隨意地與作爲 是大約1 0到大約 體溶液:多孔性微 0 . 9 ( v / v ) 合物可被製成融合 期數0 8 / 3 0 8 檔者中有描述,其 A7 B7 的 PCT 申請書W09 3/0 0 0 5 0 部內容併入本文爲參考資料。維維素蛋 約1到大約1 0% (w/v植入)的濃 多孔性微粒聚合物/纖維素使接收製劑 稀釋劑之水狀丙三醇混合,較佳的濃度 8 0 % ( v / V ):而使接吸製劑/液 粒聚合物的比例由大約0 . 1到大約 最佳。而二者擇其一的,多孔性微粒聚 的海綿狀物,在尙未審査的申請書連續 ,787,在1994年9月19日編 內容併入本文爲參考資料。和多孔性微 粒聚合物一起使用的成骨蛋白質的量一般在0. 01到 1毫克蛋白質的範圍,所使用的組成物每一立方公分所含 的蛋白質由0. 05到0. 6毫克爲較佳。 另一種較佳的載體是纖維素物質,如烷基纖維素(包 括羥基烷基織維素),包括甲基纖維素,乙基纖維素,羥 基乙基纖維素,羥基丙基纖維素,羥基丙基甲基纖維素* 以及羧基甲基纖維素,而最佳的是羧基甲基纖維素的陽離 子塩類。 在纖維素載體和膠原質凝膠的情況中,載體以水合的 纖維素黏性凝膠的型式出現較佳。黏性可藉由機械的方法 來增加,如高度的攪動一段合適的時間,接著高壓滅菌, 或是用化學方法,BMP和纖維素載體存在於合適緩衝液 的溶液中是較佳的,一種較佳的緩衝溶波是一組成物包括 4------ΪΤ------哼 (請先聞讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) 12 A7 449478 ___B7__ 五、發明説明(10) 有,除了成骨蛋白質外,大約1. 0到大約10. 0%( w/v)的胺基醋酸,大約0. 1到大約5. 0 % ( w/v )的糖類,以蔗糖較佳,大約1到大約2 0毫莫耳 的麩酸塩酸塩,以及隨著的大約0. 0 1到大約0. 1% 的非離子性界面活性劑,如聚山梨酸酯8 0。較佳的溶液 是由大約1%到大約2 Q%w/v纖維素載體/緩衝液, 如果有需要,也可加入塩類。一較佳的黏性凝膠載體在下 列實施例2中有描述,和黏性凝膠載體一起使用之成骨蛋 白質的量,一般的範圍由大約0. 05到大約1. 5毫克 ,而所需植入物質的每立方公分含有由大約0 . 1到大約 1 . 〇毫克較佳。 在本發明的方法和組成物中,對BMP S可做爲合適 於載體的其他物質包括玻尿酸,外科的網狀組織或縫合線 聚乙二醇塩,對溫度敏感的聚合物,去礦質化的骨頭,礦 物和陶製品,如磷酸鈣,塩基式磷灰石,等等。除外尙可 將上述描述之物質合併使甩。/ 然而*在本發明中一個較佳的具體表現是沒有使用載 體。取而代之的,本發明的蛋白質是存在在一合適的緩衝 液,如上列所述之中,直接適用在修復組織所需的部位。 例如,蛋白質可利用刷子或其他合適的適用物,如注射用 針筒來給予。二者擇其一地,蛋白質也可直接施於修復組 織所需的部位。 接下來的實施例更描述了本發明中使用存在於膠原質 海綿狀物載體的BMP — 2具體表現的實行。這些實施例 冢紙張尺度適用中國國家標牟(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁)
'1T 經濟部中央標準局員工消费合作社印敢 -13 - 經濟部中央標隼局貝工消費合作社印製 449470 Αν _ B7 五、發明説明() 11 並沒有限制,且將會被熟於此技藝之人士所認同,可依照 上述之詳細說明做改變。 實施例 實施例1 :在外科手術所製造的肌腱對骨頭分離損害中所 使用的BMP — 2和膠原質海綿狀物聚合物載 體 使用二十隻成年的雜種犬。將其兩個膝部接合處的長 形指狀伸肌肌腱由牠們的大腿骨止端分離出來並通過一錐 形間隙移植到基部脛骨的幹骺端。將其兩個後腿的膝部接 合處的長形指狀伸肌由牠的大腿骨止端分離出來並通過一 骨頭小管移植到基部脛骨的幹骺端。重組的人類BMP -2 (rhBMP_2)被用在一肢的肌腱與骨頭接觸面, 用類型I的膠原質海綿狀物作載體〔圖1〕。而位於對側 的肢所使用的是沒有r h BMP — 2的膠原質海綿狀物〔 對照組〕。 這些動物在手術的過程中都經麻醉,通過側生的外膝 蓋骨切口而通入膝部接合處:長形的指狀伸肌肌腱被確認 然後藉由銳利的解剖將之由位在側面的大腿髁處之止端分 離出來。然後覆蓋在脛骨肌肉頂端的筋膜就被切開,而肌 肉向側邊收縮。而在基部脛骨的幹骺端與骨頭的長軸成 45度角的地方會產生一錐形直徑4. 8毫米的間隙。
Hel istatR膠原質海綿狀物是與重組的人類BMP〜2 ( r h BMP — 2 )摻合在一起,然後此海綿狀物會包圍在 本蛾《張尺度適用中國國家椋準(CNS ) A4規格(2丨0X297公釐) " -14 ~ ----------——一------、1T------4-1 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 A74_49_47_8_B7__五、發明説明(12) 分離的肌腱外面。而肌腱沒有固定的一端被用手拉而通過 錐形間隙,在拉緊的狀態下,在基部脛骨的幹骺端的中間 面用4 一 0不銹鋼做簡單的斷續縫合而將之固定。此肌腱 很舒適的接合在骨頭小管內,並遍及整個小管的長度與骨 頭接觸。而接合處的被膜,筋膜和皮下組織用3 — 〇鉻製 的線以斷續的縫合來封閉它們,而皮廣則用3 — 0的不銹 鋼用斷續的縫合來封閉之。此步驟也在對側的膝部再做一 次。肢並未被固定,而這些狗可被允許在各自的室內奔跑 運動。 八隻犬在二和四週被犧牲掉,四隻犬在八週被犧牲掉 。髙解析度的X光片被製作,以及在光線和偏極光的顯微 鏡下,肌腱一骨頭接觸片的顯微鏡切片被偵察到。檫示有 四環黴素的切片在螢光顯微鏡下被偵察到。二週和四週的 標本,其最終失敗的生物力學試驗用一張力速率爲 5 0 . 8毫米/秒的MTS物質測試儀器來完成。而失敗 的量被平均,且有使用r h BMP — 2的一邊與對照組用 Student's paried t-test來比較。.結果:一連串的組織 學分析顯示,與僅使用膠原質載體的肢體比較,有使用 r h BMP — 2的肢在肌腱和骨頭接觸面會產生大量的纖 維組織母細胞增植,肥胖似骨母細胞的細胞,以及新的骨 頭小柱。在治療進行中,使用r hBMP — 2的肢體的接 觸面的新的骨頭小柱會成熟並更接近肌腱,而未使用 r h BMP — 2的肢體,有纖維或顆粒組織的區域,會將 肌腱和骨頭小管分離。有螢光鉻標示的標本的Von koss- (請先閲讀背面之注意事項再填寫本頁) .11 本紙張尺度適用中國國家標準(CNS ) A4規格(2!0X297公釐) 449470 A7 B7_____ 五、發明説明(13) (請先閱讀背面之注意事項再填寫本頁) a强度切片和螢光顯微鏡檢査証實了在肌腱-骨頭接觸面 的最新形成的骨頭有漸進的礦質化。在骨頭誘導的方法中 ,髙解析度的X光片証實先前存在的薄層骨頭被再吸收’ 而在四和八週的r h BMP — 2標本中新的骨頭有漸進礦 質化。而宿主對膠原質移植物的免疫學上的反應則沒有証 據。 最終失敗强度(N )的成對比較証實使用r h BMP 一 2的肢體比二週的標本(P=〇 . 0 3 5 )和四週的標
本(Ρ=0· 0 5)兩者都顯著的較强。使用rhBMP 訂 一2的肢體和對照組肢體0 0 5 )在强度上由 二週到四週有統計學上顯著的增加。〔圖2〕° 經濟部中央標準局員工消費合作杜印製 討論:骨頭成形蛋白質增加了在骨頭小管中肌腱移植物的 癒合。先前有關肌腱到骨頭癒合的硏究証實了在肌腱和骨 頭間的纖維組織接觸面。r h BMP 一 2在此接觸面組織 所誘導出的大量的新的骨頭沈澱物’會導致在較早的時間 點上骨頭對肌腱會有較緊密的接合’而使用r h BMP_ 2的肢體的肌腱和骨頭間的s h a r p e y s纖維則有"較完整的 產生。而固定所增加的强度和在使用r h BMP _ 2的肢 體中所看到的骨頭向內生長的組織學上的程度有相互關係 本紙張尺度適用中國國家標準( CNS ) A4规格(公藿) 16 A7 B7 五、發明說明( 附件1-1 : 第85106195號專利申請案中文說明書修正頁 民國90年6月呈 圖示簡要說明 圖1 :表示重組人類骨質成形蛋白質-2 (rhBMP-2)之膠原質海綿狀物載體,對 外科手術所製造的肌腱對骨頭之分離損害所產生之結締組織與骨頭之 間功能性接觸的再生作用。結果顯示’ BMP可增進肌腱對骨頭之癒合 作用。圖1右側爲肌腱-載體-骨頭之交接處的橫切面圖 圖2 :表示經rhBMP-2處理之肢體的最終失敗強度(N)的成對比較。結果證實 ΛΒΜΡ_2可雜骨頭與臓間之讎組織接觸面誘導出大量新生的骨 質沉積物 (請先閱讀背面之注意事項再填寫本頁) 裝--------訂·--------· 經 濟 部 智 慧 財 產 局 消 費 合 作 社 印 製
Claims (1)
- d 49 47 q A8 B8 C8 D8 六、申請專利範圍 1 . 一種藥學組成物,用於結締組織和骨頭間功能性 附著的再生,包含有足夠量的純化的骨頭成形蛋白質( bmp),可造成結締組織到骨頭間功能性附著的再生。 2 .如申請專利範圍第1項之組成物,其中此組成物 包含有存在於合適載體的重組人類BMP — 2。 3 .如申請專利範圍第2項之組成物,其中此載體包 含有一膠原質海綿狀物。 4 .如申請專利範圍第2項之組成物,其中此載體是 由集围中被選出的,包括有: a)膠原質海綿狀物: b )纖維素黏性凝膠:以及 c )多孔性微粒聚合物和使接收劑。 5 .如申請專利範圍第4項之組成物,其中此載體包 含有多孔性微粒聚合物和使接收劑是由含有纖維素物質和 自體血液的集團中選出的。 6.如申請專利範圍第1項之組成物,更包含了一種 蛋白質能夠在部位誘導形成似肌腱或似韌帶之組織。 7 .如申請專利範圍第6項之組成物,其中此組成物 包含有存在於合適的載體中之BMP-2和BMP-12 〇 8 . —種藥學組成物,用於結締組織和骨頭間功能性 附著之再生,包含有由集團中所選出的一或多個BMP s ,包括有 a ) Β Μ P ~ 2 ; -17 - {請先閲讀背面之注意事項再填寫本頁) 訂 經濟部中央標準局員工消費合作社印製 本紙張尺度適用中國國家標準{ CNS ) Α4規格(210Χ297公釐) J^47b_^__ 六、申請專利範圍 b) BMP-12:以及 c) BMP — 2和BMP — 2之異質二量體。 9. 一種藥學組成物,用於肌腱和骨頭間功能性附著 的苒生,包含有一有效量之骨頭成形蛋白質。 1 0 .如申請專利範圍第9項之組成物,其包含有存 在於合適載體中之重組人類BMP - 2。 1 1 .如申請專利範圍第1 0項之組成物,其中此載 體包含有膠原質海綿狀物。 12. 如申請專利範圍第10項之組成物,其中此載 體是由隻團中選出的,包括有: a )膠原質海綿狀物: b )織維素黏性凝膠;以及 c )多孔性微粒聚合物和使接收劑。 13. 如申請專利範圍第12項之組成物,其中此載 體包含有多孔性微粒聚合物和使接收劑是由含有纖維素物 質和自體血液之集團中選出的。 經濟部中央標準局員工消費合作社印製 14. 如申請專利範圍第9項之組成物,更包含了一 種蛋白質能夠在部位誘導形成似肌腱或似韌帶之組織。 1 5 .如申請專利範圍第1 4項之組成物,其中此組 成物包含有存在於合適載體中之BMP — 2和BMP — 12° 1 6 .—種藥學組成物,用於肌腱和骨頭間功能性附 著的再生,包含有一/或多個由集團中選出之BMPs , 包括有: 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) {請先閲讀背面之注意事項再填寫本頁) -18 - ^9478 六、申請專利範圍 a ) Β Μ P - 2 ; b c ρ ΡΜ Μ Β Β 及 P 以 Μ ., Β和 2 2 體量 二質異之 2 ΤΧ (請先閱讀背面之注意事項再填寫本頁) 訂 吹 I . 經濟.那中央標準局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) Α·4規格(210X297公釐} 9 li 449478 附件2-1 : 第8 5 1 0 6 1 9 5號專利申請案中文圖式修正本 民國9 0年6月呈 圖 含有BMP-2之 膠原質海綿狀物膠原質 海綿狀物 腱 1/2 4句478 腱失敗强度 (suo:IA3sq:®«2週2/2 A7 B7 五、發明說明( 附件1-1 : 第85106195號專利申請案中文說明書修正頁 民國90年6月呈 圖示簡要說明 圖1 :表示重組人類骨質成形蛋白質-2 (rhBMP-2)之膠原質海綿狀物載體,對 外科手術所製造的肌腱對骨頭之分離損害所產生之結締組織與骨頭之 間功能性接觸的再生作用。結果顯示’ BMP可增進肌腱對骨頭之癒合 作用。圖1右側爲肌腱-載體-骨頭之交接處的橫切面圖 圖2 :表示經rhBMP-2處理之肢體的最終失敗強度(N)的成對比較。結果證實 ΛΒΜΡ_2可雜骨頭與臓間之讎組織接觸面誘導出大量新生的骨 質沉積物 (請先閱讀背面之注意事項再填寫本頁) 裝--------訂·--------· 經 濟 部 智 慧 財 產 局 消 費 合 作 社 印 製449478 附件2-1 : 第8 5 1 0 6 1 9 5號專利申請案中文圖式修正本 民國9 0年6月呈 圖 含有BMP-2之 膠原質海綿狀物膠原質 海綿狀物 腱 1/2
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46249795A | 1995-06-05 | 1995-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW449478B true TW449478B (en) | 2001-08-11 |
Family
ID=23836637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW085106195A TW449478B (en) | 1995-06-05 | 1996-05-24 | Pharmaceutical compositions for healing and repair of connective tissue attachment |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6187742B1 (zh) |
| EP (3) | EP1364656B1 (zh) |
| JP (1) | JPH11507032A (zh) |
| KR (1) | KR100440645B1 (zh) |
| CN (1) | CN1133462C (zh) |
| AT (1) | ATE245996T1 (zh) |
| AU (1) | AU699918B2 (zh) |
| CA (1) | CA2220555C (zh) |
| DE (1) | DE69629294T2 (zh) |
| DK (2) | DK0831884T3 (zh) |
| ES (2) | ES2440441T3 (zh) |
| FI (1) | FI116511B (zh) |
| HU (1) | HU222664B1 (zh) |
| OA (1) | OA10547A (zh) |
| PT (1) | PT831884E (zh) |
| TW (1) | TW449478B (zh) |
| WO (1) | WO1996039169A1 (zh) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150328A (en) | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
| WO1993009229A1 (en) | 1991-11-04 | 1993-05-13 | Genetics Institute, Inc. | Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
| US20080139474A1 (en) * | 1991-11-04 | 2008-06-12 | David Israel | Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
| US6291206B1 (en) | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
| AU689184B2 (en) | 1993-12-07 | 1998-03-26 | Genetics Institute, Llc | BMP-12, BMP-13 and tendon-inducing compositions thereof |
| US5906827A (en) * | 1994-06-03 | 1999-05-25 | Creative Biomolecules, Inc. | Matrix for the manufacture of autogenous replacement body parts |
| US6083522A (en) * | 1997-01-09 | 2000-07-04 | Neucoll, Inc. | Devices for tissue repair and methods for preparation and use thereof |
| JP4388602B2 (ja) * | 1997-02-07 | 2009-12-24 | ストライカー コーポレイション | マトリクスを含まない骨形成デバイス、移植片、およびその使用方法 |
| US20010016646A1 (en) | 1998-03-20 | 2001-08-23 | David C. Rueger | Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects |
| US7041641B2 (en) | 1997-03-20 | 2006-05-09 | Stryker Corporation | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
| CN1068793C (zh) * | 1997-04-17 | 2001-07-25 | 中国人民解放军第四军医大学全军创伤骨科研究所 | 骨生长刺激素注射剂及其制备方法 |
| EP0896825B1 (en) | 1997-08-14 | 2002-07-17 | Sulzer Innotec Ag | Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors |
| US6727224B1 (en) | 1999-02-01 | 2004-04-27 | Genetics Institute, Llc. | Methods and compositions for healing and repair of articular cartilage |
| DK1223990T3 (da) | 1999-10-15 | 2004-11-29 | Inst Genetics Llc | Formuleringer af hyaluronsyre til tilförsel af osteogene proteiner |
| US6626945B2 (en) | 2000-03-14 | 2003-09-30 | Chondrosite, Llc | Cartilage repair plug |
| US6632246B1 (en) | 2000-03-14 | 2003-10-14 | Chondrosite, Llc | Cartilage repair plug |
| WO2001070288A2 (en) * | 2000-03-23 | 2001-09-27 | Genetics Institute, Inc. | Thermoreversible polymers for delivery and retention of osteoinductive proteins |
| US6878166B2 (en) * | 2000-08-28 | 2005-04-12 | Ron Clark | Method and implant for securing ligament replacement into the knee |
| US20030082233A1 (en) * | 2000-12-01 | 2003-05-01 | Lyons Karen M. | Method and composition for modulating bone growth |
| US20020114795A1 (en) * | 2000-12-22 | 2002-08-22 | Thorne Kevin J. | Composition and process for bone growth and repair |
| US7226587B2 (en) | 2001-06-01 | 2007-06-05 | Wyeth | Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins |
| TWI267378B (en) | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
| ES2247423T5 (es) | 2001-11-19 | 2015-12-30 | Scil Technology Gmbh | Método de producción de un dispositivo recubierto homogéneamente que tiene propiedades osteoinductoras y osteoconductoras |
| EP1578348A4 (en) * | 2002-02-08 | 2011-03-16 | Wyeth Llc | PREPARATION CONTAINING BIOACTIVE AGENTS AND METHOD OF USE |
| TWI282283B (en) * | 2002-05-17 | 2007-06-11 | Wyeth Corp | Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins |
| US7622562B2 (en) * | 2002-06-26 | 2009-11-24 | Zimmer Orthobiologics, Inc. | Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue |
| ATE322916T1 (de) * | 2002-09-10 | 2006-04-15 | Scil Technology Gmbh | Unter verringerter sauerstoffkonzentration mit einem osteoinduktiven protein beschichtetes metallimplantat |
| JP5392981B2 (ja) | 2003-09-12 | 2014-01-22 | ワイス・エルエルシー | 骨形成蛋白の送達のための注入可能なリン酸カルシウム固体ロッドおよびペースト |
| US7896917B2 (en) * | 2003-10-15 | 2011-03-01 | Biomet Sports Medicine, Llc | Method and apparatus for graft fixation |
| WO2005086706A2 (en) * | 2004-03-05 | 2005-09-22 | The Trustees Of Columbia University In The City Of New York | Multi-phased, biodegradable and osteointegrative composite scaffold for biological fixation of musculoskeletal soft tissue to bone |
| US8002778B1 (en) | 2004-06-28 | 2011-08-23 | Biomet Sports Medicine, Llc | Crosspin and method for inserting the same during soft ligament repair |
| WO2006081379A1 (en) * | 2005-01-26 | 2006-08-03 | Wyeth | Use of sfrps as markers of bmp activity |
| EP1863518A2 (en) * | 2005-03-30 | 2007-12-12 | Wyeth | Methods for stimulating hair growth by administering bmps |
| US20060287676A1 (en) * | 2005-06-15 | 2006-12-21 | Rita Prajapati | Method of intra-operative coating therapeutic agents onto sutures, composite sutures and methods of use |
| US20060286289A1 (en) * | 2005-06-15 | 2006-12-21 | Rita Prajapati | Method of intraoperative coating therapeutic agents onto sutures |
| US20060287675A1 (en) * | 2005-06-15 | 2006-12-21 | Prajapati Rita T | Method of intra-operative coating therapeutic agents onto sutures composite sutures and methods of use |
| US20100047309A1 (en) * | 2006-12-06 | 2010-02-25 | Lu Helen H | Graft collar and scaffold apparatuses for musculoskeletal tissue engineering and related methods |
| AU2007234612B2 (en) * | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
| US7718616B2 (en) | 2006-12-21 | 2010-05-18 | Zimmer Orthobiologics, Inc. | Bone growth particles and osteoinductive composition thereof |
| US8753391B2 (en) | 2007-02-12 | 2014-06-17 | The Trustees Of Columbia University In The City Of New York | Fully synthetic implantable multi-phased scaffold |
| US8147546B2 (en) | 2007-03-13 | 2012-04-03 | Biomet Sports Medicine, Llc | Method and apparatus for graft fixation |
| US8075562B2 (en) * | 2007-06-25 | 2011-12-13 | Wisconsin Alumni Research Foundation | Controlled release of biopharmaceutical growth factors from hydroxyapatite coating on bioresorbable interference screws used in cruciate ligament reconstruction surgery |
| US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
| JP5323832B2 (ja) | 2007-08-07 | 2013-10-23 | アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー | 酸性水溶液中にgdf−5を含むタンパク質製剤 |
| BRPI0911048A2 (pt) * | 2008-04-14 | 2015-12-29 | Atrm Llc | formulações líquidas tamponadas de gdf-5 |
| US20130122066A1 (en) | 2010-07-30 | 2013-05-16 | Biopham Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Drug delivery devices and growth factor formulations for accelerated wound healing |
| US8613938B2 (en) | 2010-11-15 | 2013-12-24 | Zimmer Orthobiologics, Inc. | Bone void fillers |
| EP2537538A1 (en) | 2011-06-22 | 2012-12-26 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH | Bioresorbable Wound Dressing |
| US20160296664A1 (en) | 2013-04-12 | 2016-10-13 | The Trustees Of Columbia University In The City Of New York | Methods for host cell homing and dental pulp regeneration |
| US10610570B2 (en) * | 2014-07-09 | 2020-04-07 | Mayo Foundation For Medical Education And Research | Treating rotator cuff conditions |
| WO2017011762A1 (en) | 2015-07-16 | 2017-01-19 | Mayo Foundation For Medical Education And Research | Treating rotator cuff conditions |
| CN110893250B (zh) * | 2019-10-11 | 2022-03-15 | 许和平 | 瘢痕/粘连阻挡膜及其制备方法和用途 |
| US12310928B2 (en) | 2020-11-16 | 2025-05-27 | University Of Utah Research Foundation | Enthesis healing |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5108922A (en) | 1986-07-01 | 1992-04-28 | Genetics Institute, Inc. | DNA sequences encoding BMP-1 products |
| IL83003A (en) * | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US4877864A (en) | 1987-03-26 | 1989-10-31 | Genetics Institute, Inc. | Osteoinductive factors |
| US5013649A (en) | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
| ZA874681B (en) | 1986-07-01 | 1988-04-27 | Genetics Inst | Novel osteoinductive factors |
| US5187076A (en) | 1986-07-01 | 1993-02-16 | Genetics Institute, Inc. | DNA sequences encoding BMP-6 proteins |
| US5106748A (en) | 1986-07-01 | 1992-04-21 | Genetics Institute, Inc. | Dna sequences encoding 5 proteins |
| US5024841A (en) | 1988-06-30 | 1991-06-18 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| US5256418A (en) | 1990-04-06 | 1993-10-26 | Organogenesis, Inc. | Collagen constructs |
| WO1991018098A1 (en) | 1990-05-16 | 1991-11-28 | Genetics Institute, Inc. | Bone and cartilage inductive proteins |
| WO1992009697A1 (en) * | 1990-11-30 | 1992-06-11 | Celtrix Laboratories, Inc. | USE OF A BONE MORPHOGENETIC PROTEIN IN SYNERGISTIC COMBINATION WITH TGF-β FOR BONE REPAIR |
| US5206028A (en) | 1991-02-11 | 1993-04-27 | Li Shu Tung | Dense collagen membrane matrices for medical uses |
| DE69213739T2 (de) | 1991-06-21 | 1997-02-20 | Genetics Institute, Inc., Cambridge, Mass. | Osteogene proteine enthaltende arzneimittel |
| EP0592562B1 (en) | 1991-06-25 | 1999-01-07 | Genetics Institute, Inc. | Bmp-9 compositions |
| US5171579A (en) | 1991-10-11 | 1992-12-15 | Genetics Institute, Inc. | Formulations of blood clot-polymer matrix for delivery of osteogenic proteins |
| WO1993009229A1 (en) | 1991-11-04 | 1993-05-13 | Genetics Institute, Inc. | Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
| DK0625989T3 (da) | 1992-02-12 | 2000-06-26 | Bioph Biotech Entw Pharm Gmbh | DNA-sekvenser kodende for hidtil ukendte vækst-/differentieringsfaktorer |
| WO1994006399A1 (en) * | 1992-09-15 | 1994-03-31 | Creative Biomolecules, Inc. | Morphogen-induced periodontal tissue regeneration |
| EP0690871A4 (en) | 1993-01-12 | 1999-10-20 | Univ Johns Hopkins Med | GROWTH DIFFERENTIATION FACTOR-5 |
| US5808007A (en) | 1993-01-12 | 1998-09-15 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-3 |
| CA2153653C (en) | 1993-01-12 | 2010-12-07 | Se-Jin Lee | Growth differentiation factor-9 |
| DK0690873T3 (da) | 1993-03-19 | 2003-09-29 | Univ Johns Hopkins Med | Vækstdifferentieringsfaktor-8 |
| WO1994026892A1 (en) | 1993-05-12 | 1994-11-24 | Genetics Institute, Inc. | Bmp-11 compositions |
| JPH09501305A (ja) | 1993-05-12 | 1997-02-10 | ジェネティックス・インスティテュート・インコーポレイテッド | Bmp−10組成物 |
| FR2706749B1 (fr) | 1993-06-23 | 1995-08-25 | Oreal | Brosse pour appliquer un produit de maquillage, en particulier du mascara |
| AU688779B2 (en) | 1993-07-09 | 1998-03-19 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-7 |
| WO1995001801A1 (en) | 1993-07-09 | 1995-01-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-6 |
| AU689184B2 (en) * | 1993-12-07 | 1998-03-26 | Genetics Institute, Llc | BMP-12, BMP-13 and tendon-inducing compositions thereof |
| US5906827A (en) * | 1994-06-03 | 1999-05-25 | Creative Biomolecules, Inc. | Matrix for the manufacture of autogenous replacement body parts |
| US5635372A (en) * | 1995-05-18 | 1997-06-03 | Genetics Institute, Inc. | BMP-15 compositions |
-
1996
- 1996-05-21 EP EP03015894.3A patent/EP1364656B1/en not_active Expired - Lifetime
- 1996-05-21 PT PT96916513T patent/PT831884E/pt unknown
- 1996-05-21 AU AU59234/96A patent/AU699918B2/en not_active Expired
- 1996-05-21 EP EP10179024A patent/EP2289536A1/en not_active Withdrawn
- 1996-05-21 EP EP96916513A patent/EP0831884B1/en not_active Revoked
- 1996-05-21 CA CA2220555A patent/CA2220555C/en not_active Expired - Lifetime
- 1996-05-21 KR KR1019970708278A patent/KR100440645B1/ko not_active Expired - Lifetime
- 1996-05-21 CN CNB961944358A patent/CN1133462C/zh not_active Expired - Lifetime
- 1996-05-21 DK DK96916513T patent/DK0831884T3/da active
- 1996-05-21 WO PCT/US1996/007282 patent/WO1996039169A1/en not_active Ceased
- 1996-05-21 DK DK03015894.3T patent/DK1364656T3/da active
- 1996-05-21 JP JP9500616A patent/JPH11507032A/ja not_active Withdrawn
- 1996-05-21 ES ES03015894.3T patent/ES2440441T3/es not_active Expired - Lifetime
- 1996-05-21 ES ES96916513T patent/ES2203701T3/es not_active Expired - Lifetime
- 1996-05-21 HU HU9802556A patent/HU222664B1/hu active IP Right Grant
- 1996-05-21 AT AT96916513T patent/ATE245996T1/de active
- 1996-05-21 DE DE69629294T patent/DE69629294T2/de not_active Revoked
- 1996-05-24 TW TW085106195A patent/TW449478B/zh not_active IP Right Cessation
-
1997
- 1997-12-02 FI FI974395A patent/FI116511B/fi not_active IP Right Cessation
- 1997-12-05 OA OA70152A patent/OA10547A/en unknown
-
1999
- 1999-03-23 US US09/274,575 patent/US6187742B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69629294D1 (de) | 2003-09-04 |
| KR19990014932A (ko) | 1999-02-25 |
| CA2220555A1 (en) | 1996-12-12 |
| HUP9802556A1 (hu) | 1999-03-29 |
| FI974395A0 (fi) | 1997-12-02 |
| CA2220555C (en) | 2011-07-19 |
| EP0831884B1 (en) | 2003-07-30 |
| FI116511B (fi) | 2005-12-15 |
| HU222664B1 (hu) | 2003-09-29 |
| DE69629294T2 (de) | 2004-04-29 |
| EP1364656A2 (en) | 2003-11-26 |
| FI974395L (fi) | 1997-12-02 |
| CN1133462C (zh) | 2004-01-07 |
| DK1364656T3 (da) | 2013-12-16 |
| CN1186438A (zh) | 1998-07-01 |
| ES2440441T3 (es) | 2014-01-29 |
| WO1996039169A1 (en) | 1996-12-12 |
| ATE245996T1 (de) | 2003-08-15 |
| AU5923496A (en) | 1996-12-24 |
| EP1364656A3 (en) | 2003-12-10 |
| KR100440645B1 (ko) | 2004-09-18 |
| HK1017841A1 (zh) | 1999-12-03 |
| ES2203701T3 (es) | 2004-04-16 |
| EP2289536A1 (en) | 2011-03-02 |
| EP0831884A1 (en) | 1998-04-01 |
| OA10547A (en) | 2002-05-31 |
| DK0831884T3 (da) | 2003-11-03 |
| JPH11507032A (ja) | 1999-06-22 |
| EP1364656B1 (en) | 2013-11-20 |
| HUP9802556A3 (en) | 1999-04-28 |
| PT831884E (pt) | 2003-11-28 |
| AU699918B2 (en) | 1998-12-17 |
| US6187742B1 (en) | 2001-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW449478B (en) | Pharmaceutical compositions for healing and repair of connective tissue attachment | |
| JP4477702B2 (ja) | 骨の修復のための骨形成デバイスおよびその使用 | |
| Wang et al. | The effect of shock wave treatment at the tendon–bone interface—An histomorphological and biomechanical study in rabbits | |
| Rodeo et al. | Use of recombinant human bone morphogenetic protein-2 to enhance tendon healing in a bone tunnel | |
| Giannoudis et al. | The synergistic effect of autograft and BMP-7 in the treatment of atrophic nonunions | |
| Keating et al. | Minimal internal fixation and calcium-phosphate cement in the treatment of fractures of the tibial plateau: a pilot study | |
| JP4121558B2 (ja) | 形態形成タンパク質および刺激因子を使用する組成物および治療方法 | |
| KIRKER‐HEAD | Recombinant bone morphogenetic proteins: novel substances for enhancing bone healing | |
| CN101432030A (zh) | 带有一个或多个贮液器的医疗用移植物 | |
| JP2005513030A (ja) | 医薬組成物及びep2受容体選択的アゴニストの投与方法 | |
| Hao et al. | Local injection of bone mesenchymal stem cells and fibrin glue promotes the repair of bone atrophic nonunion in vivo | |
| RU2727241C2 (ru) | Образование кости | |
| Hsu et al. | The use of demineralized bone matrix for anterior cruciate ligament reconstruction: a radiographic, histologic, and immunohistochemical study in rabbits | |
| Duan et al. | Repair of rabbit femoral defects with a novel BMP2-derived oligopeptide P24 | |
| CN100435859C (zh) | 用于关节软骨愈合和修复的骨软骨移植物的制备方法和组合物 | |
| Shapiro | Overview of deformities | |
| HK1017841B (zh) | 用於修复和愈合连接组织附着的方法和组合物 | |
| ES3028409T3 (en) | A tissue sealant for use in anterior cruciate ligament (acl) reconstruction | |
| Abu | Evaluation of the effects of intramuscular implantation of avian demineralized bone matrix (ADBM) and the use of ADBM in created ulna defects managed by the intramedullary pin-external skeletal fixator (IM-ESF) tie-in technique in pigeons (Columba livia domestica) | |
| FI20055480A7 (fi) | BMP-4-, BMP-12-, BMP-13-ja MP-52-polypeptidien käyttö valmistettaessa sidekudoskiinnityksen regenerointiin tarkoitettuja farmaseuttisia koostumuksia | |
| HK40019925B (zh) | 自体骨移植物替代物 | |
| Ferretti | The Repair of Segmental Mandibular Defects by a Bone Morphogenetic Protein Bone Device in Man |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD4A | Issue of patent certificate for granted invention patent | ||
| MK4A | Expiration of patent term of an invention patent |